ClinicalTrials.gg
CompletedNCT03399721KOSNARUpdated Sep 22, 2023

Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis

An interventional study of Chordate S101 and Chordate S101 Placebo in Nasal Congestion and Non-allergic Rhinitis, sponsored by Chordate Medical. Completed at 13 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Chordate Medical · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an interventional, multicenter, double-blind, placebo-controlled trial in which patients diagnosed with non-allergic rhinitis will be randomized to either intranasal stimulation, or placebo treatment with the Chordate System at two occasions.

Read the detailed description

This is a double-blind, placebo-controlled, multi-center study in which patients diagnosed with non-allergic rhinitis will receive intranasal stimulation with the Chordate System at two occasions. Objectives are to evaluate the efficacy of the procedure in reducing disease specific symptoms such as nasal congestion, rhinorrhea, nasal itching and sneezing, but also to investigate the influence on quality of life, safety and tolerability.

02

Conditions studied

  • Nasal Congestion
  • Non-allergic Rhinitis
03

In context

Nasal Obstruction

173 studies on the registry are indexed under Nasal Obstruction; 31 are open to participants now.

This study's enrollment of 279 is above the median of 70 across 139 interventional studies indexed under Nasal Obstruction.

Browse Nasal Obstruction studies →

Lead sponsor

Chordate Medical is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with persistent (>12w) symptoms of non-allergic rhinitis dominated by nasal congestion (± secretion) for an average of at least 1 h per day for at least 5 days during a period of 14 days.
  2. Having nasal congestion as major symptom, and a median nasal congestion score of at least 2 (scale 0-3)
  3. Male or female 18 - 65 years
  4. Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history and physical examination.
  5. Willing and able to provide written prior to participation in the clinical investigation
  6. Willing and able to comply with all study related procedures

Exclusion criteria

Exclusion Criteria:

  1. Patients with Allergic rhinitis, demonstrated by either positive skin prick test, Phadiatop or RAST during the last year.
  2. Ongoing respiratory tract infection including nasal cavity at inclusion
  3. Systemic treatment less than 4 weeks before the inclusion in the study
  4. Patients with a history of nasal surgery like: septoplasty, cosmetic surgery, conchal surgery or any other nasal surgery except closed reposition for nasal fracture during last year
  5. History of frequent nose bleeds or a condition that increases the risk of excessive bleeding
  6. Pronounced anterior septal deviation or other significant nasal pathology at endoscopic examination
  7. Current of any kind
  8. Known allergy to polyvinylchloride or medicinal liquid paraffin
  9. Any disease, condition (medical or surgical) or drug or alcohol abuse which, in the opinion of the investigator, might compromise the study results, or would place the patient at increased risk.
  10. Any implant with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulation, spinal stimulator, bone growth stimulator, or cochlear implant or any other implant in the head-, and neck region.
  11. Previous treated with radiation on the face, head or neck regions
  12. Female patients who are pregnant or become pregnant at any time from inclusion of the study until end of the 8 week follow-up visit
  13. Received study drug in a clinical trial for an drug within the previous 30 days, or 5 half-lives, whichever is longer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
279 participants (actual)

Study arms

  • Active comparator
    Chordate S101 Active

    Active treatment With Device Chordate S101

    Device: Chordate S101

  • Placebo comparator
    Chordate S101 Placebo

    Placebo treatment With Device Chordate S101

    Device: Chordate S101 Placebo

Interventions

  • DeviceChordate S101

    Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time

  • DeviceChordate S101 Placebo

    Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.

06

What researchers measure

Primary outcomes

  1. Nasal congestion

    The primary performance endpoint is the responder rate based on the change in the weekly median nasal congestion score (taken from Total Nasal Symptom Score (TNSS)) from baseline to the 3 month follow-up visit

    Time frame: 3 month

07

Study locations

13 sites
  • Charles University Faculty of Medicine in Hradec Králové
    Hradec Králové, Czechia
  • Hospital Pardubice
    Pardubice, Czechia
  • Charles University Motol University Hospital
    Prag, Czechia
  • Helsinki University Hospital
    Helsinki, Finland
  • Kuopio University Hospital
    Kuopio, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Aristotle University
    Thessaloniki, Greece
  • Azienda Ospedaliera di Padova
    Padova, Italy
  • Fondazione Policlinico A Gemelli
    Rome, Italy
  • Academisch Medisch Centrum Amsterdam
    Amsterdam, Netherlands
  • University Hospital Birmingham
    Birmingham, United Kingdom
  • James Paget University Hospital
    Great Yarmouth, United Kingdom
  • Guys Hospital, Greate Maze Pond
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Sep 2022, 52 months.

Of 60 interventional studies with no phase under Nasal Obstruction, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 16, 2018
StartActual
May 7, 2018
Primary completionActual
Sep 30, 2022
CompletionActual
Sep 30, 2022
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03399721
Lead sponsor
Chordate Medical
Responsible party
Sponsor
First posted
Jan 16, 2018
Start date
May 7, 2018
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Last update
Sep 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion